药明康德

药明康德

制药业

Shanghai,Shanghai 71,253 位关注者

The global pharmaceutical and medical device open-access capability and technology platform

关于我们

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

所属行业
制药业
规模
超过 10,001 人
总部
Shanghai,Shanghai
类型
上市公司
创立
2000
领域
Drug Discovery、Bioanalytical、Lab Testing、Clinical and Regulatory、API Development and Manufacturing、Drug Development、Biological Reagents、Biologics、Medical Device、Chemistry、Toxicology、Cell and Gene Therapy和Contract Research Organization

地点

药明康德员工

动态

  • 查看药明康德的公司主页,图片

    71,253 位关注者

    This December marks WuXi AppTec’s 24th anniversary! For 24 years, our belief that “every drug can be made and every disease can be treated” has continued to inspire us as we look to the future with determination and optimism. Starting from a single laboratory, we have grown into a global enterprise with 32 R&D and manufacturing sites worldwide, dedicated to advancing breakthroughs in life-sciences. Thank you to our customers, partners, and global teams - your commitment to our mission of enabling transformative solutions has been the heartbeat of our success. Together, we’re not just imagining a healthier world - we are building it.

    • WuXi AppTec’s 24th anniversary
  • 查看药明康德的公司主页,图片

    71,253 位关注者

    As we mark Thanksgiving in the United States, we wanted to extend our gratitude to our global teams for their dedication and to our customers worldwide for their continued trust and support. Together, we are driving innovation, bringing hope and advancements to patients, striving towards a healthier world. This season is a reminder of our shared goals and the positive impact we make together.   Happy #Thanksgiving to those in the United States!

    • Happy Thanksgiving 2024 from WuXi AppTec
  • 查看药明康德的公司主页,图片

    71,253 位关注者

    We are proud to announce that WuXi AppTec has received a gold medal in the 2024 EcoVadis Sustainability Rating, placing us in the top 2% of all participating companies! This achievement reflects our commitment to sustainability and our ongoing efforts to integrate environmental and social responsibilities throughout our operations. Looking ahead, we will continue to advance #ESG efforts, support customers in delivering innovative therapies, and create a lasting, positive impact on the healthcare industry.  Read more: https://lnkd.in/ee26vAbR

    • WuXi AppTec Receives Gold Medal in 2024 EcoVadis Sustainability Rating
  • 查看药明康德的公司主页,图片

    71,253 位关注者

    Antimicrobial resistance (AMR) is one of the most critical global health challenges of the 21st century. The World Health Organization warns that by 2050, AMR could cause 10 million deaths annually, surpassing cancer as the leading cause of death. At WuXi AppTec, we are committed to supporting global efforts to address this issue. Learn more about AMR from leading experts at Wellcome Trust, AMR Action Fund, CARB-X, Roche, Massachusetts Institute of Technology. https://lnkd.in/efTmVm9m

    WXPress: for WuXi news and R&D insights

    WXPress: for WuXi news and R&D insights

    wxpress.wuxiapptec.com

  • 查看药明康德的公司主页,图片

    71,253 位关注者

    Congratulations to our WuXi Chemistry facility in Couvet, Switzerland!  Incredible recognition for diligent work meeting our shared global #ESG responsibilities.

    查看WuXi Chemistry的公司主页,图片

    17,274 位关注者

    We're thrilled to share that our facility in Couvet, Switzerland has received a silver medal in the 2024 business sustainability ratings by EcoVadis!  This achievement underscores our unwavering commitment to integrating Environmental, Social, and Governance (#ESG) priorities into our strategy and operations.   As a state-of-the-art pharmaceutical production facility, our Couvet site plays a vital role in WuXi AppTec’s #CRDMO model by providing clinical and commercial scale production capability for oral solid dosage forms. Designed with industry-leading energy efficiency and environmental standards, the site was built to support future sustainable growth.    Through this facility and others, WuXi STA enables innovation across Europe, helping our partners bring life-changing treatment to patients worldwide.   https://lnkd.in/eCKHgZu4

    • 该图片无替代文字
  • 查看药明康德的公司主页,图片

    71,253 位关注者

    Thank you to those who attended our WuXi Night last week during BIO-Europe 2024 in Stockholm. The demand for new and better medicines remains unchanged. Let us look forward with hope and a shared commitment to transform more scientific discoveries into innovative therapies for patients, striving to our vision that “every drug can be made and every disease can be treated”.

    • WuXi Night Stockholm 2024 during BIO Europe
  • 查看药明康德的公司主页,图片

    71,253 位关注者

    We are honored to announce that WuXi AppTec has been ranked #1 in the global Life Sciences Tools & Services sector in the 2024 S&P Global Corporate Sustainability Assessment (CSA), as of November 11, 2024! We achieved a 2024 CSA score of 80 out of 100 points, an impressive 11-point increase over 2023. The company received full marks in 43 out of 102 areas evaluated in the CSA.   This achievement demonstrates WuXi AppTec’s success in enhancing our capability to address ESG-related risks and opportunities across our global operations. By embedding ESG initiatives at the core, we are contributing to a healthier and more sustainable world.   Stay tuned for more exciting updates! https://lnkd.in/efSma98c #ESG #Sustainability #CSA

    • WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment
  • 查看药明康德的公司主页,图片

    71,253 位关注者

    Happy #WorldCitiesDay!   Our global presence spans diverse cities, each playing a vital role in advancing health innovation. Today, we celebrate not just the cities where we operate, but the incredible people who make it all possible.   Worldwide, our employees are sharing what they cherish about WuXi AppTec in their native languages. Their messages reflect our unwavering commitment to delivering life-saving treatments and making a meaningful impact for patients.   WuXi AppTec is a proud global community dedicated to advancing the future of healthcare.   Let's keep building a healthier world together.

  • 查看药明康德的公司主页,图片

    71,253 位关注者

    Thank you, Frost & Sullivan, for awarding us the 2024 Global Contract Research, Development and Manufacturing Organization Company of the Year Award. This is a proud moment for us! This marks the 8th consecutive year that WuXi AppTec has received this award. We are deeply honored by the recognition, which underscores how we meet customers’ needs through our comprehensive #CRDMO model. By continuously enhancing our capabilities and capacity, we support seamless drug development from discovery to commercialization, enabling the industry to bring more groundbreaking therapies to patients around the world. https://lnkd.in/e-suw_fP

  • 药明康德转发了

    WuXi AppTec's 2024 Investor Day was an incredible success. I’m grateful to Florence Shi, Edward Hu and Minzhang Chen for organizing such an outstanding event. Each year, we must be sensitive to trends to embrace the future – adapting our capabilities to drive innovation and sustain development. By generating flow, understanding trends, and providing coordinated capabilities, we create significant value for our customers. To our investors and talented individuals around the company, your contributions and collaboration are invaluable as we continue to deliver for patients. https://lnkd.in/gkAvkFJE

    • 该图片无替代文字

关联主页

相似主页